Amgen’s November 3 earnings will test whether growing medicine sales can keep offsetting competition and supporting investment in future treatments. The company has confirmed its third-quarter report for after close.
Read the full research in the app
A subscription is required to access the full thread.
Open in the app →Financials
Technicals
Earnings-peers